Industry Says FDA Should Broaden Scope Of Pre-Submission Program

FDA should allow pre-submission meetings to occur earlier in a device’s development cycle than what is stated in the recent draft guidance, industry groups say. The agency should also agree to review prior data as part of these meetings.